| Literature DB >> 27155887 |
Emil Chiauzzi1, Pronabesh DasMahapatra2, Elisenda Cochin2, Mikele Bunce3, Raya Khoury3, Purav Dave3.
Abstract
BACKGROUND: Providers and healthcare organizations have begun recognizing the importance of patient empowerment as a driver of patient-centered care. Unfortunately, most studies have investigated empowerment with single diseases. Identifying factors of empowerment across conditions and populations would enable a greater understanding of this construct.Entities:
Mesh:
Year: 2016 PMID: 27155887 PMCID: PMC5107186 DOI: 10.1007/s40271-016-0171-2
Source DB: PubMed Journal: Patient ISSN: 1178-1653 Impact factor: 3.883
Fig. 1Study participation process. Overall, 21,923 participants viewed the invitation, of whom 6872 patients electronically consented to participate in the survey; 15,051 did not respond or opted out. Among consented patients, 1535 were excluded box (duplicates = 3, asked to be removed after consent n = 1, did not meet the eligibility criteria = 1531). Of the remaining 5337 participants, 3988 completed the survey; 1349 abandoned the survey after starting. The view rate (views/invites), participation rate (participants/views), and completion rate (completers/participants) were 7, 24, and 75 %, respectively
Demographic characteristics of the study population
| Completers ( | Non-completers ( | Test statistica |
| |
|---|---|---|---|---|
| Age [years; mean ± SD] | 52.5 ± 12.2 | 51.2 ± 12.8 | 3.2 | 0.001 |
| Number of self-reported conditions [median (IQR)] | 2 (1–4) | 1 (1–2) | 10.4 | <0.0001 |
| Gender [% ( | 0.1 | 0.706 | ||
| Female | 72 (2883) | 65 (882) | ||
| Male | 28 (1094) | 26 (344) | ||
| Unreported | <1 (11) | 9 (123) | ||
| Race [% ( | 9.2 | 0.002 | ||
| White | 90 (3594) | 79 (1071) | ||
| Non-White | 8 (321) | 10 (133) | ||
| Unreported | 2 (73) | 11 (145) | ||
| Education [% ( | 6.8 | 0.033 | ||
| Less than college | 16 (638) | 16 (212) | ||
| Attended college | 62 (2462) | 52 (701) | ||
| Advanced degree | 20 (817) | 15 (203) | ||
| Unreported | 2 (71) | 17 (233) | ||
| Health Insurance [% ( | 12.7 | <0.001 | ||
| Yes | 90 (3602) | 72 (974) | ||
| No | 7 (267) | 8 (110) | ||
| Unreported | 3 (119) | 20 (265) | ||
| Work status [% ( | 13.1 | <0.001 | ||
| Medically unable to work | 37 (1464) | 26 (356) | ||
| Able to work | 61 (2423) | 57 (765) | ||
| Unreported | 2 (101) | 17 (228) | ||
| Region [% ( | 13.1 | 0.004 | ||
| US | 69 (2744) | 60 (810) | ||
| UK | 13 (534) | 14 (193) | ||
| Canada | 8 (323) | 6 (79) | ||
| Other | 9 (379) | 11 (145) | ||
| Unreported | <1 (8) | 9 (122) | ||
| Primary condition [% ( | 108.7 | 0.018 | ||
| Fibromyalgia | 20 (814) | 22 (301) | ||
| Multiple sclerosis | 19 (766) | 16 (213) | ||
| Parkinson’s disease | 8 (319) | 7 (89) | ||
| Type 2 diabetes mellitus | 5 (193) | 6 (76) | ||
| Epilepsy | 4 (165) | 3 (37) | ||
| Amyotrophic lateral sclerosis | 3 (110) | 4 (48) | ||
| Rheumatoid arthritis | 3 (123) | 2 (33) | ||
| Systemic lupus erythematosus | 3 (100) | 2 (33) | ||
| Major depressive disorder | 2 (95) | 2 (33) | ||
| Idiopathic pulmonary fibrosis | 2 (90) | 2 (27) | ||
| Myalgic encephalomyelitis/chronic fatigue syndrome | 2 (76) | 3 (45) | ||
| Migraine | 2 (64) | 2 (25) | ||
| Bipolar disorder type 2 | 1 (55) | 1 (17) | ||
| Other | 24 (979) | 29 (398) | ||
| Interference in activities of daily living (often–always) [% ( | 78 (3094) | – | ||
| Prediagnosis healthcare involvement (important–very important) [% ( | 87 (3504) | – |
SD standard deviation, IQR interquartile range
aTest statistics for the difference between completers and non-completers were computed using available profile data only (excluding unreported). The test statistic is t test for age, Wilcoxon two-sample z test for condition count (non-normal distribution), and Chi-square test for categorical data. Multiplicity adjustments were not performed
Exploratory factor analysis and internal consistency of the empowerment itemsa
| Items/questions | Positive Patient–Provider Interaction (Factor 1) (Cronbach’s | Knowledge and Personal Control (Factor 2) (Cronbach’s |
|---|---|---|
| How satisfied are you with the relationship you have with the healthcare provider who treats your primary condition? |
| |
| Are you satisfied with the follow-up care you receive from the healthcare provider who treats your primary condition? |
| |
| How much trust do you have in the competence of the healthcare provider who treats your primary condition? |
| |
| To what extent do you feel your main healthcare provider monitors your ongoing care? |
| |
| How much do your treatment goals match with your healthcare providers’ treatment plan? |
| 0.47 |
| How much of the health information you received from healthcare providers during your visits was clear and easy to understand? |
| 0.45 |
| How much say do you think you have in making decisions about your treatment? |
| 0.44 |
| How much of the information that you receive in the educational materials during your visits is clear and easy to understand? |
| 0.42 |
| I am aware of the warning signs/symptoms related to my primary health condition |
| |
| I feel confident in managing any warning signs/symptoms of my primary health condition |
| |
| I am well-informed about the available treatment options for my primary health condition | 0.49 |
|
| I know how my primary condition progresses over time |
| |
| I have as much support as I need from friends to help care for and manage my condition |
| |
|
|
| |
| I have as much family support I need to help care for and manage my condition |
| |
| Of the health information about test results and medical reports you receive, how much of it is clear and easy to understand? | 0.45 |
|
Bold numbers represent loadings of items 1–8 on Factor 1, and items 9–16 on Factor 2. Psychometric testing of factors demonstrated acceptable Cronbach’s α for each subscale (α > 0.79)
aEFA identified two components; principal axis factoring followed by promax rotation was run using the two-factor solution. Sixteen (n = 16) items loaded >0.4
bItem 14 (in italics) was removed due to poor discriminant validity, as measured by corrected item-to-total correlation (correlations between items and total domain score with the item excluded in the domain total; not shown in the table)
Mean empowerment scores (total and factor level) with 95 % CIs across sociodemographic strata
| Positive Patient–Provider Interaction Score [mean (95 % CI)] | Knowledge and Personal Control Score [mean (95 % CI)] | Total Empowerment Score [mean (95 % CI)] | |
|---|---|---|---|
| Age categories, years | |||
| 18–34 Gen Y | 30.2 (29.4–30.9) | 25.7 (25.1–26.2) | 56.5 (55.3–57.7) |
| 35–44 Gen X | 30.2 (29.6–30.8) | 25.6 (25.2–26.0) | 56.7 (55.8–57.6) |
| 45–54 young boomers | 31.6 (31.2–32.0) | 26.5 (26.2–26.8) | 58.5 (57.9–59.2) |
| 55–64 old boomers | 32.3 (31.9–32.7) | 27.1 (26.8–27.3) | 59.9 (59.4–60.5) |
| 65–74 silent generation | 33.8 (33.3–34.2) | 28.0 (27.7–28.4) | 62.1 (61.3–62.8) |
| 75–100 GI generation | 33.5 (32.2–34.7) | 27.8 (26.7–28.8) | 61.9 (59.9–63.9) |
| Gender | |||
| Male | 32.5 (32.1–32.9) | 27.8 (27.5–28.1) | 60.7 (60.1–61.3) |
| Female | 31.6 (31.3–31.8) | 26.4 (26.2–26.5) | 58.5 (58.1–58.9) |
| Health insurance | |||
| Yes | 32.1 (31.9–32.3) | 26.9 (26.7–27.0) | 59.5 (59.1–59.8) |
| No | 28.2 (27.1–29.3) | 24.9 (24.2–25.6) | 54.3 (52.7–55.9) |
| Education | |||
| High school or less | 30.8 (30.2–31.4) | 26.2 (25.8–26.6) | 57.9 (56.9–58.8) |
| College | 31.9 (31.6–32.2) | 26.6 (26.4–26.8) | 59.0 (58.6–59.5) |
| Advanced education | 32.7 (32.3–33.1) | 27.7 (27.4–28.0) | 60.7 (60.1–61.4) |
| Work status | |||
| Able to work | 32.0 (31.7–32.3) | 27.1 (26.9–27.3) | 59.7 (59.3–60.1) |
| Medically unable to work | 31.7 (31.3–32.0) | 26.2 (25.9–26.5) | 58.5 (57.9–59.0) |
| Primary condition | |||
| Fibromyalgia | 29.7 (29.1–30.2) | 24.8 (24.5–25.2) | 55.3 (54.4–56.1) |
| Multiple sclerosis | 33.1 (32.7–33.5) | 27.8 (27.5–28.1) | 60.3 (60.7–61.9) |
| Parkinson’s disease | 33.5 (32.9–34.1) | 28.0 (27.5–8.5) | 61.8 (60.9–62.7) |
| Type 2 diabetes mellitus | 32.6 (31.7–33.5) | 27.4 (26.7–28.1) | 60.8 (59.4–62.2) |
| Epilepsy | 30.9 (29.8–32.0) | 26.7 (26.0–27.5) | 58.0 (56.3–59.7) |
| Bipolar disorder type 2 | 32.2 (30.5–33.8) | 26.6 (25.3–27.9) | 58.1 (55.4–60.9) |
| Rheumatoid arthritis | 32.3 (31.1–33.5) | 26.9 (26.1–27.7) | 59.5 (57.7–61.3) |
| Amyotrophic lateral sclerosis | 33.0 (31.7–34.3) | 28.4 (27.7–29.1) | 61.2 (59.2–63.1) |
| Systemic lupus erythematosus | 29.4 (27.9–30.9) | 25.6 (24.6–26.6) | 55.7 (53.3–58.1) |
| Major depressive disorder | 30.5 (28.9–31.6) | 24.5 (23.6–25.5) | 55.7 (53.8–57.5) |
| Idiopathic pulmonary fibrosis | 33.0 (31.7–34.3) | 28.0 (27.1–28.9) | 61.1 (59.2–63.1) |
| Myalgic encephalomyelitis/chronic fatigue syndrome | 28.6 (26.5–30.7) | 24.7 (23.4–26.0) | 54.8 (51.7–58.0) |
| Migraine | 30.8 (29.1–32.5) | 25.8 (24.7–26.9) | 57.3 (54.9–59.8) |
Participants had the option of choosing not to respond to the survey questions. Scores are computed on all available data
Statistically significant difference (p < 0.05) is noted if the 95 % CI between strata do not overlap. For example, the 95 % CI for the total empowerment score ranges from 60.1 to 61.3 in males and from 58.1 to 58.9 in females. As the intervals do not overlap, the difference is statistically significant
EFA exploratory factor analysis, CI confidence interval
Fig. 2Analysis of means with Nelson–Hsu adjustment analysis of empowerment scores by primary condition. Numbers indicate difference from the overall weighted sample mean. Statistical significance after Nelson–Hsu adjustment is denoted by an asterisk (***p < 0.001, **p < 0.01, *p < 0.05)
| Clinicians: Greater attention needs to be paid to helping clinicians provide sufficient time to develop mutually acceptable treatment goals with patients, as well as attend to informational needs in difficult-to-treat conditions. |
| Patients: Educating patients about the importance of seeking support to improve knowledge and a sense of control may enhance empowerment, particularly in difficult-to-manage chronic conditions. |
| Researchers: Interpersonal and intrapersonal factors in empowerment have been identified but further research is needed to examine causal relationships among key constructs. |